Company Analysis
Sign in

Regencell Bioscience Holdings Limited (RGC)

Nasdaq: RGC · Medicinal Chemicals & Botanical Products · Hong Kong · filing with the SEC since 2020
Full chart Alerts Compare
Grade6.3
◀ Past 6.3● Present 5.5▶ Future 7.2
7 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyfiscal 2026, as filed
Revenuen/a
Net income-$11.7M-226.5%
Earnings per share$-2.37-229.2%
Operating cash flow-$7.7M-147.2%
Cash$14.2M+486.7%
Debtn/a
Shareholders’ equity$13.3M+174.7%
Shares, dilutedn/a
Return on equity-87.7%
The recordfrom its filings
Filings in 202621
Newest filingOct 7 · 20-F
Annual reportOct 7, 2026
Quarterly reportn/a
Next report due20-F by Oct 28
Insider sales, 12 months$0.00
Insider buys, 12 months$0.00
Patents grantedn/a
Filer categoryLarge accelerated filer
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
1920212223242526
As filed, in USD. Nothing here is a forecast.

News

May 29, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
May 29, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
May 19, 2026 · SEC EDGAR · Form 424B5
Shelf offering
Open the filing on sec.gov
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton RGC · research, not advice